Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066157 | 0.80 | ACVRL1 (0.38) | MAPK1MEN1KMT2AKDM4CACVRL1 | |
| SCHEMBL20851569 | 0.79 | HRH3 (0.41) | MEN1KMT2ACYP11B2ACVRL1HRH3 | |
| SCHEMBL20851239 | 0.79 | HRH3 (0.41) | MEN1KMT2ACYP11B2ACVRL1HRH3 | |
| SCHEMBL4066382 | 0.78 | DRD2 (0.40) | MEN1KMT2ACYP11B2HRH3 | |
| SCHEMBL9523155 | 0.74 | TAS1R3 (0.49) | MTNR1BMTNR1AMEN1KMT2AKDM4C | |
| SCHEMBL10841331 | 0.72 | OPRK1 (0.36) | MEN1KMT2A | |
| SCHEMBL18163016 | 0.71 | FNTA (0.37) | — | |
| SCHEMBL29640806 | 0.71 | HDAC1 (0.45) | MAPK1 | |
| SCHEMBL2688968 | 0.71 | HDAC1 (0.45) | MAPK1 | |
| SCHEMBL11733028 | 0.70 | SIRT1 (0.39) | MEN1KMT2ACYP11B2KDM4CSIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2016-08-11 | — | — | US | disclosed |
| US-20150038509-A1 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy | ANORMED, INC. (CA) | 2015-02-05 | — | — | US | disclosed |
| US-8778967-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120301427-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORPORATION | 2012-11-29 | — | — | US | disclosed |
| EP-1317445-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-03-11 | — | — | EP | disclosed |
| US-20080167341-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-7396840-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-6864265-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2005-03-08 | — | — | US | disclosed |
| WO-2004106493-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-04 | — | — | US | disclosed |
| EP-1465889-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | AnorMED Inc. (CA) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2004-01-29 | — | — | US | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
| WO-2003055876-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2003-07-10 | — | — | WO | disclosed |
| EP-1317445-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002022600-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167341-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | HPGDS 236/4885MAPK1 1397/4885MTNR1B 1912/4885 |
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | HPGDS 115/4885MAPK1 1891/4885MTNR1B 408/4885 |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | HPGDS 236/4885MAPK1 1397/4885MTNR1B 1912/4885 |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | HPGDS 236/4885MAPK1 1397/4885MTNR1B 1912/4885 |
| US-20150038509-A1 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy | CCR5, CXCR4, CXCR3 | HPGDS 236/4885MAPK1 1397/4885MTNR1B 1912/4885 |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | HPGDS 115/4885MAPK1 1891/4885MTNR1B 408/4885 |
| US-20120301427-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | HPGDS 160/4885MAPK1 1535/4885MTNR1B 1841/4885 |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | HPGDS 236/4885MAPK1 1397/4885MTNR1B 1912/4885 |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | HPGDS 236/4885MAPK1 1397/4885MTNR1B 1912/4885 |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | HPGDS 236/4885MAPK1 1397/4885MTNR1B 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.